Dexter de Leon, MD
Interventional Cardiology · Tucson, AZNPI 1598965907
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $44,999 of the $74,346 with a category attached, or 60.5%. It is spread thinly across 41 manufacturers, the largest accounting for just 23.4%. Reporting peaked in 2019 at $21,201 and has fallen 66.3% since, to $7,152 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,095 payments — averaging $67.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$17K
- Abiomed$13K
- Abbott$11K
- Boston Scientific$10K
- Medtronic$5K
- Philips North America LLC$4K
- plus $13K from 35 others
Across 24 payments — averaging $671.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$16K
What the payments were for
- Speaking & faculty fees$16,80023%
- Travel & lodging$12,51017%
- Food & beverage$44,99961%
- Education$360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coronary Orbital Atherectomy System$16,973
- Impella$8,399
- MitraClip$2,052
- CoreValve Evolut$1,711
- Mitra Clip system$1,592
- Watchman$1,516
- PASCAL$1,500
- WATCHMAN FLX$1,346
- GENERAL - THERAPIES$1,240
- Spectranetics Undiv$1,200
- WATCHMAN Access System$1,046
- TRICLIP$985
- Indigo System$665
- PORTICO$559
- FLOWTRIEVER CATHETER, S$526
- SAPIEN 3 Ultra RESILIA$508
- Sublime 014 Rx PTA Balloon Dilatation Catheter$438
- Sublime Microcatheter, 018, 200cm, Straight$438
- Pounce Thrombectomy System$438
- Pounce Thrombectomy$438
How this compares
$74,346 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $210,625 |
| EliquisApixaban | 160 | $207,961 |
| XareltoRivaroxaban | 108 | $153,311 |
| EntrestoSacubitril/Valsartan | 71 | $92,401 |
| JardianceEmpagliflozin | 30 | $35,817 |
| MounjaroTirzepatide | 25 | $32,665 |
| Repatha SureclickEvolocumab | 28 | $26,468 |
| MultaqDronedarone Hcl | 12 | $22,936 |
| Metoprolol Succinate | 548 | $5,860 |
| Losartan Potassium | 468 | $4,337 |
| Rosuvastatin Calcium | 328 | $3,910 |
| Carvedilol | 432 | $3,814 |
| Amiodarone Hcl | 145 | $3,259 |
| ClopidogrelClopidogrel Bisulfate | 310 | $3,073 |
| Atorvastatin Calcium | 310 | $3,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $154 | $210,625143 claims |
| PfizerEliquis | $117 | $207,961160 claims |
| Johnson & JohnsonXarelto | $261 | $153,311108 claims |
| NovartisEntresto | $662 | $92,40171 claims |
| Boehringer IngelheimJardiance | $34 | $35,81730 claims |
| Lilly USA, LLCMounjaro | $15 | $32,66525 claims |
| Sanofi-aventis U.S. LLCMultaq | $31 | $22,93612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$617K
- Kapildeo LotunTucson$365K
- Neil GheewalaTucson$141K
- William ThomasTucson$56K
- Ranjith ShettyTucson$50K
- Santiago RamirezTucson$45K
- Sulaiman RathoreTucson$32K
- Michel CorbanTucson$27K
- Sundeep ShenoyTucson$24K
- Paul SorajjaPhoenix$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.